{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-24-000022","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.548093+00:00","generated_at":"2026-06-05T05:43:12.965908+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immuneering reports $85.7M cash, net loss $53.5M in 2023; trial milestones ahead","bullets":["Cash, cash equivalents and marketable securities $85.7M as of Dec 31, 2023; cash runway into 2H 2025.","Net loss Q4 2023 $15.1M ($0.52 per share); full year net loss $53.5M ($1.88 per share).","FDA Fast Track designation for IMM-1-104 in pancreatic cancer received Feb 2024.","Topline Phase 1 data for IMM-1-104 expected March 2024; first patient in Phase 2a expected March 2024.","First patient dosing in Phase 1/2a trial of IMM-6-415 expected March 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-24-000022","json":"https://secwatch.observer/filing/0001790340-24-000022.json","markdown":"https://secwatch.observer/filing/0001790340-24-000022.md","text":"https://secwatch.observer/filing/0001790340-24-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034024000022/0001790340-24-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034024000022/imrx-20240301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:43:12.965908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59ad501013e5c17f4f7d432ea89559463a534337","claim":"Immuneering Corp reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1790340/000179034024000022/0001790340-24-000022-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}